The authors point out the clinical usefulness and optimal tolerability of Fentiazac in patients suffering from tuberculosis and whose condition requires therapeutic intervention with non-steroid anti-inflammatory drugs.
Get full access to this article
View all access options for this article.
References
1.
CeruttiSGalimbertiE (in press) ‘Influenza di nuovi antinfiammatori verso il complemento’. Gazzetta Medica Italiana
2.
d'AtriGGalimbertiECeruttiSForlaniA (1975) Attivita antinfiammatoria e antidolorifica di una nuova molecola di sintesi: l'acido 2-fenil-4-p. clorofenil-tiazol-5-ilacetico. Bollettino Chimico Farmaceutico114, 107
3.
DaviesJEKellettDWPenningtonJC (1976) The anti-inflammatory and analgesic effects of Norvedan a novel, non-steroidal agent. Archives Internationales de Pharmacodynamie et de Thérapie221, 274
4.
GalimbertiECeruttiSForlaniAd'AtriG (1976) Histopathological and pharmacological studies on the action of a new anti-inflammatory agent (BR 700). Arzneimittel-Forschung26, 392
MirelliEFicheraGTittobelloA (1974) Valuation of the anti-inflammatory activity of a new drug on the gastroduodenal and rectal mucosa. Acta Endoscopica et Radiocinematographica4, 149
7.
PernaGNataleF (in press) Uso della benzidamina nella pratica tisiologica. Clinica Terapeutica
8.
RossiFDi NolaRCazzolaMSpadaroR (1974) Valutazione dell'attivita antireazionale, antipiretica ed antidolorifica del BR 700 somministrato per via rettalle. Gazzetta Medica Italiana133, 87
